Proteinuria after kidney transplantation

Claudio Ponticelli, Giorgio Graziani

Research output: Contribution to journalArticle

Abstract

The prevalence of proteinuria at 1 year after renal transplantation ranges between 11% and 45% and is even higher in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). Two main mechanisms can lead to proteinuria: an inadequate reabsorption of small proteins from proximal tubular cells damaged by ischemia-reperfusion injury, rejection, or toxic agents (tubular proteinuria) or an increased passage of albumin and/or protein with higher molecular weight (MW) because of a disruption of glomerular barrier caused by recurrent or de novo glomerulonephritis, transplant glomerulopathy, chronic rejection, or CNI toxicity (glomerular proteinuria). Proteinuric patients have worse patient and graft survival rates in comparison to non proteinuric patients. The amount of proteinuria is a reliable predictor of the allograft outcome. However, even microalbuminuria may be associated with a poor outcome. Treatment of proteinuria mainly rests on the management of the etiologic cause. Inhibitors of renin-angiotensin system (RAS) are useful in reversing microalbuminuria and can reduce proteinuria, but their efficacy in interfering with patient or graft survival is not demonstrated.

Original languageEnglish
Pages (from-to)909-917
Number of pages9
JournalTransplant International
Volume25
Issue number9
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Proteinuria
Kidney Transplantation
Graft Survival
Poisons
Sirolimus
Renin-Angiotensin System
Glomerulonephritis
Reperfusion Injury
Allografts
Albumins
Proteins
Survival Rate
Molecular Weight
Transplants

Keywords

  • angiotensin-converting enzyme inhibitors
  • microalbuminuria
  • mTOR inhibitors and proteinuria
  • post-transplant proteinuria
  • proteinuria
  • tubular proteinuria

ASJC Scopus subject areas

  • Transplantation

Cite this

Proteinuria after kidney transplantation. / Ponticelli, Claudio; Graziani, Giorgio.

In: Transplant International, Vol. 25, No. 9, 09.2012, p. 909-917.

Research output: Contribution to journalArticle

Ponticelli, Claudio ; Graziani, Giorgio. / Proteinuria after kidney transplantation. In: Transplant International. 2012 ; Vol. 25, No. 9. pp. 909-917.
@article{c6403cb5d8574376bd60f72eb0750ea4,
title = "Proteinuria after kidney transplantation",
abstract = "The prevalence of proteinuria at 1 year after renal transplantation ranges between 11{\%} and 45{\%} and is even higher in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). Two main mechanisms can lead to proteinuria: an inadequate reabsorption of small proteins from proximal tubular cells damaged by ischemia-reperfusion injury, rejection, or toxic agents (tubular proteinuria) or an increased passage of albumin and/or protein with higher molecular weight (MW) because of a disruption of glomerular barrier caused by recurrent or de novo glomerulonephritis, transplant glomerulopathy, chronic rejection, or CNI toxicity (glomerular proteinuria). Proteinuric patients have worse patient and graft survival rates in comparison to non proteinuric patients. The amount of proteinuria is a reliable predictor of the allograft outcome. However, even microalbuminuria may be associated with a poor outcome. Treatment of proteinuria mainly rests on the management of the etiologic cause. Inhibitors of renin-angiotensin system (RAS) are useful in reversing microalbuminuria and can reduce proteinuria, but their efficacy in interfering with patient or graft survival is not demonstrated.",
keywords = "angiotensin-converting enzyme inhibitors, microalbuminuria, mTOR inhibitors and proteinuria, post-transplant proteinuria, proteinuria, tubular proteinuria",
author = "Claudio Ponticelli and Giorgio Graziani",
year = "2012",
month = "9",
doi = "10.1111/j.1432-2277.2012.01500.x",
language = "English",
volume = "25",
pages = "909--917",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Blackwell Publishing Ltd",
number = "9",

}

TY - JOUR

T1 - Proteinuria after kidney transplantation

AU - Ponticelli, Claudio

AU - Graziani, Giorgio

PY - 2012/9

Y1 - 2012/9

N2 - The prevalence of proteinuria at 1 year after renal transplantation ranges between 11% and 45% and is even higher in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). Two main mechanisms can lead to proteinuria: an inadequate reabsorption of small proteins from proximal tubular cells damaged by ischemia-reperfusion injury, rejection, or toxic agents (tubular proteinuria) or an increased passage of albumin and/or protein with higher molecular weight (MW) because of a disruption of glomerular barrier caused by recurrent or de novo glomerulonephritis, transplant glomerulopathy, chronic rejection, or CNI toxicity (glomerular proteinuria). Proteinuric patients have worse patient and graft survival rates in comparison to non proteinuric patients. The amount of proteinuria is a reliable predictor of the allograft outcome. However, even microalbuminuria may be associated with a poor outcome. Treatment of proteinuria mainly rests on the management of the etiologic cause. Inhibitors of renin-angiotensin system (RAS) are useful in reversing microalbuminuria and can reduce proteinuria, but their efficacy in interfering with patient or graft survival is not demonstrated.

AB - The prevalence of proteinuria at 1 year after renal transplantation ranges between 11% and 45% and is even higher in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). Two main mechanisms can lead to proteinuria: an inadequate reabsorption of small proteins from proximal tubular cells damaged by ischemia-reperfusion injury, rejection, or toxic agents (tubular proteinuria) or an increased passage of albumin and/or protein with higher molecular weight (MW) because of a disruption of glomerular barrier caused by recurrent or de novo glomerulonephritis, transplant glomerulopathy, chronic rejection, or CNI toxicity (glomerular proteinuria). Proteinuric patients have worse patient and graft survival rates in comparison to non proteinuric patients. The amount of proteinuria is a reliable predictor of the allograft outcome. However, even microalbuminuria may be associated with a poor outcome. Treatment of proteinuria mainly rests on the management of the etiologic cause. Inhibitors of renin-angiotensin system (RAS) are useful in reversing microalbuminuria and can reduce proteinuria, but their efficacy in interfering with patient or graft survival is not demonstrated.

KW - angiotensin-converting enzyme inhibitors

KW - microalbuminuria

KW - mTOR inhibitors and proteinuria

KW - post-transplant proteinuria

KW - proteinuria

KW - tubular proteinuria

UR - http://www.scopus.com/inward/record.url?scp=84864643813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864643813&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2012.01500.x

DO - 10.1111/j.1432-2277.2012.01500.x

M3 - Article

C2 - 22616794

AN - SCOPUS:84864643813

VL - 25

SP - 909

EP - 917

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 9

ER -